14:00 Fri 20 Mar 2020
GlaxoSmithKline PLC - Directorate Change
Issued:
GSK appoints
Charlie has recently retired from a successful career at Bristol Myers Squibb (BMS) where he held a number of leadership roles in commercial, strategy and finance. Beginning his career at BMS in 1984, he held positions of increasing responsibility within the finance organisation and had commercial operational responsibility for
Charlie served as a member of the Board of Colgate-Palmolive Company from 2017 until
On joining the Board Charlie will become a member of the
Commenting on the appointment, Sir
Notes
1. | The appointment of
| |
2. | The Board determined that
| |
3. | He will receive the standard basic fee for a Non-Executive Director of
| |
4. | Membership of other Committees will be determined in due course.
| |
5. |
| |
6. | There are no additional details to disclose in respect of
| |
7. | From
| |
| Sir Dr Dr Dr Dr | Non-Executive Chairman Chief Executive Officer Chief Financial Officer Chief Scientific Officer and President, R&D Senior Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director |
About GSK
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com/about-us.
GSK enquiries: |
|
|
|
| | +44 (0) 20 8047 5502 | ( |
| | +44 (0) 20 8047 5502 | ( |
|
|
|
|
US Media enquiries: | | +1 202 603 5003 | ( |
|
|
|
|
Analyst/Investor enquiries: | | +44 (0) 208 047 5194 | ( |
| | +44 (0) 20 8047 7562 | ( |
| | +44 (0) 20 8047 2406 | ( |
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Principal risks and uncertainties' in the company's Annual Report on Form 20-F for 2019.
Registered in
No. 3888792
Registered Office:
Brentford,
TW8 9GS
This information is provided by RNS, the news service of the
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
FOR OUR FULL DISCLAIMER CLICK HERE